"Precision Oncology Drug Portfolio Market Summary:
According to the latest report published by Data Bridge Market Research, the Precision Oncology Drug Portfolio Market
The global precision oncology drug portfolio market size was valued at USD 18.76 billion in 2025 and is expected to reach USD 45.46 billion by 2033, at a CAGR of 11.70% during the...
Clinical Oncology Next Generation Sequencing Industry Insights:
Straits Research recently introduced the latest update on the Clinical Oncology Next Generation Sequencing Market that provides an extensive outlook of the market, analyzing key growth opportunities, challenges, risk factors, and emerging trends across diverse geographic regions. The report offers a definitive and meticulous...
According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...
According to a new report from Intel Market Research, the global Cabozantinib Drug market was valued at USD 2.12 billion in 2025 and is projected to reach USD 4.01 billion by 2034, growing at a robust CAGR of 7.5% during the forecast period (2026–2034). This growth is propelled by the escalating global burden of cancer, particularly renal and liver cancers, alongside expanding clinical...
According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...
According to a new report from Intel Market Research, the global Selpercatinib Capsules market was valued at USD 420 million in 2025 and is projected to reach USD 820 million by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is propelled by the increasing prevalence of RET-altered cancers, growing adoption of biomarker-driven therapies, and...
English
Indonesia
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek